(VIANEWS) – MEDISTIM (MEDI.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| MEDISTIM (MEDI.OL) | kr180.00 | 2.56% | 24.73% |
| EQUASENS (EQS.PA) | €51.30 | 2.06% | 27.25% |
| SARTORIUS STED BIO (DIM.PA) | €264.30 | 0.34% | 8.15% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. MEDISTIM (MEDI.OL)
2.56% Forward Dividend Yield and 24.73% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Europe, Asia, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and imaging probes for intraoperative use. It also provides QuickFit TTFM probes, which is designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation of fragile or calcified vessels; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical equipment. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr5.6.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 32.14. Meaning, the purchaser of the share is investing kr32.14 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.73%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Apr 25, 2024, the estimated forward annual dividend rate is 4.5 and the estimated forward annual dividend yield is 2.56%.
More news about MEDISTIM.
2. EQUASENS (EQS.PA)
2.06% Forward Dividend Yield and 27.25% Return On Equity
Equasens Société anonyme provides healthcare IT solutions in Europe. It offers id. PATIENT, a business software; id. MOBILITY, a back-office management software; pandaLAB Pro, an instant messaging solution; Id. VENTE, an HAS-certified drug database; Id. COMMANDE, an order management module; dispensing robots; Services Ségur id; id. DOSAGE, a dosage management and printing module; multimeds reconditioning robot; compliance monitoring module; home delivery module; home equipment rental management module; Visiodroits module; and Website connector. The company also provides id. DESK, an informative and interactive dashboard; id. UP!, a real-time monitoring and control application of id management software; id. EASYQ, a queue management solution; Miaterapia; Id. SHOW, an application for managing real-time communications on pharmacy screens; Pharmaweb; TsGatePro; LMO, a dispensary business software; and LGO, a dispensary management software. In addition, it offers DOMILINK HAD software; mobiSOINS mobility tool; MEMORialis, support software for alzheimer's monitoring teams; HOSPILINK, an hospital information system applications; HOSPILINK DPI, a computerized patient file; HOSPILINK LOOKUP Big Data; eNephro solutions; NOVIAcare solutions; KAP&LINK2, a contact chip card reader terminal and NFC reader; eS-KAP-Ad, a connected nomadic tool incorporating software; KAP-INSIDE, a mobile terminal; and TI-KAP allowing access to contact and contactless cards. Further, the company provides AUTHENTICATOR, a patented authentication system; KAP'TEUR by KAPELSE, a patented universal sensor; ExpressVitale; MédiStory, that automates the transfer of invoicing to the healthcare professional's accounting. Additionally, it offers medical telesecretarial services for healthcare professionals, as well as equipment lease financing solutions. The company was incorporated in 1996 and is headquartered in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
Earnings Per Share
As for profitability, EQUASENS has a trailing twelve months EPS of €3.2.
PE Ratio
EQUASENS has a trailing twelve months price to earnings ratio of 16.03. Meaning, the purchaser of the share is investing €16.03 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.25%.
Moving Average
EQUASENS’s worth is below its 50-day moving average of €54.93 and way under its 200-day moving average of €61.41.
More news about EQUASENS.
3. SARTORIUS STED BIO (DIM.PA)
0.34% Forward Dividend Yield and 8.15% Return On Equity
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €3.36.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 78.66. Meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.15%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SARTORIUS STED BIO’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for SARTORIUS STED BIO is 48852 which is 29.49% below its average volume of 69287.
Revenue Growth
Year-on-year quarterly revenue growth declined by 8.2%, now sitting on 2.72B for the twelve trailing months.
More news about SARTORIUS STED BIO.
